WO2005012912A3 - Expression de lamp-1 par des cellules cancereuses - Google Patents

Expression de lamp-1 par des cellules cancereuses Download PDF

Info

Publication number
WO2005012912A3
WO2005012912A3 PCT/US2004/023055 US2004023055W WO2005012912A3 WO 2005012912 A3 WO2005012912 A3 WO 2005012912A3 US 2004023055 W US2004023055 W US 2004023055W WO 2005012912 A3 WO2005012912 A3 WO 2005012912A3
Authority
WO
WIPO (PCT)
Prior art keywords
lamp
cancer cells
reducing
cancer cell
proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/023055
Other languages
English (en)
Other versions
WO2005012912A2 (fr
Inventor
Eleni Venetsanakos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of WO2005012912A2 publication Critical patent/WO2005012912A2/fr
Publication of WO2005012912A3 publication Critical patent/WO2005012912A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés permettant de détecter une cellule cancéreuse ainsi que des procédés permettant de diminuer la prolifération d'une cellule cancéreuse. Afin de diminuer la prolifération, ce procédé consiste à mettre en contact la cellule néoplasique avec un agent de liaison cytotoxique ou cytostatique spécialement réactif avec LAMP-1, une protéine membranaire associée au lysosome exprimée dans la membrane de la cellule cancéreuse. L'invention concerne également un procédé permettant de diminuer la croissance tumorale à travers le ciblage d'un agent cytotoxique mettant en oeuvre un anticorps spécifique pour LAMP-1 ainsi qu'un procédé de détection de cellules cancéreuses exprimant LAMP-1, afin d'aider au diagnostic.
PCT/US2004/023055 2003-07-25 2004-07-16 Expression de lamp-1 par des cellules cancereuses Ceased WO2005012912A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49011203P 2003-07-25 2003-07-25
US60/490,112 2003-07-25

Publications (2)

Publication Number Publication Date
WO2005012912A2 WO2005012912A2 (fr) 2005-02-10
WO2005012912A3 true WO2005012912A3 (fr) 2005-06-30

Family

ID=34115358

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/023055 Ceased WO2005012912A2 (fr) 2003-07-25 2004-07-16 Expression de lamp-1 par des cellules cancereuses

Country Status (1)

Country Link
WO (1) WO2005012912A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611703B1 (en) * 2006-03-13 2009-11-03 Celera Corporation Kidney disease targets and uses thereof
EP3400961B1 (fr) * 2012-12-27 2021-02-24 Sanofi Anticorps anti-lamp1 et conjugués anticorps médicament, et utilisations associées
AU2022339819A1 (en) * 2021-09-03 2024-04-11 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
CN120535634A (zh) * 2025-06-10 2025-08-26 扬州大学 一种抗lamp1的小鼠单克隆抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004048537A2 (fr) * 2002-11-25 2004-06-10 Exelixis, Inc. « lamps » modifiant la voie p53 et leurs procedes d'utilisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004048537A2 (fr) * 2002-11-25 2004-06-10 Exelixis, Inc. « lamps » modifiant la voie p53 et leurs procedes d'utilisation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BONEHILL AUDE ET AL: "Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules", JOURNAL OF IMMUNOLOGY, vol. 172, no. 11, 1 June 2004 (2004-06-01), pages 6649 - 6657, XP001205558, ISSN: 0022-1767 *
DO K-Y ET AL: "LAMP-1 IN CHO CELLS IS A PRIMARY CARRIER OF POLY-N-ACETYLLACTOSAMINE CHAINS AND IS BOUND PREFERENTIALLY BY A MAMMALIAN S-TYPE LECTIN", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 173, no. 3, 1990, pages 1123 - 1128, XP009045077, ISSN: 0006-291X *
JONES KIMBERLY L ET AL: "Chediak-Higashi lymphoblastoid cell lines: Granule characteristics and expression of lysosome-associated membrane proteins", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 65, no. 3, 1992, pages 219 - 226, XP001205557, ISSN: 0090-1229 *
WOYNAROWSKA B ET AL: "Inhibition of lectin-mediated ovarian tumor cell adhesion by sugar analogs", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 269, no. 36, 9 September 1994 (1994-09-09), pages 22797 - 22803, XP002971638, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2005012912A2 (fr) 2005-02-10

Similar Documents

Publication Publication Date Title
WO2002031507A3 (fr) Analyse enzymatique non invasive d'etats associes au remodelage d'un tissu
WO2007146172A8 (fr) Anticorps reconnaissant un épitope contenant un hydrate de carbone du cd-43 et de l'ace exprimé sur des cellules cancéreuses, et procédés les utilisant
WO2004037999A3 (fr) Adn et proteines 3 de type a34 et a33, anticorps associes et methodes de traitement associees
WO2004031411A3 (fr) Genes et polypeptides associes aux cancers du pancreas chez l'homme
WO2004075855A3 (fr) Procede de traitement in vivo de cibles biologiques specifiques dans un fluide corporel
EP2028270A3 (fr) Virus de vaccin recombiné modifié et utilisations associées
WO2006090750A8 (fr) Anticorps anti-igsf4 et son utilisation
WO2004000094A8 (fr) Marqueurs predictifs utilises dans le traitement du cancer
WO2009004484A3 (fr) Modulateur de p53 et cible cancereuse
WO2004009622A3 (fr) Complexes de proteiniques de reseaux cellulaires fondant le developpement du cancer et d'autres maladies
WO2005010213A3 (fr) Marqueurs pour la detection du cancer de l'estomac
WO2006097743A3 (fr) Procede
WO2004069211A3 (fr) Proteines d'affinite destinees a l'application controlee de substances cosmetiques
WO2005040421A3 (fr) Marqueurs de pronostic et de diagnostic des troubles de proliferation cellulaire dans les tissus mammaires
BRPI0407680A (pt) métodos para diagnóstico de cáncer e diminuição de metástase por células cancerosas
BRPI9912227B8 (pt) método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método.
WO2004052392A3 (fr) Immunotherapie anticancereuse
WO2003092601A3 (fr) Procede pour detecter les maladies liees au stockage lysosomal
WO2003066663A3 (fr) Peptides utilises pour reconnaitre et cibler des tumeurs de cellules gliales
AU2003228984A1 (en) Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells
EP2192132A3 (fr) Anticorps et partenaires de liaison anti-il-20, anti-il-22 et anti-il-22ra, et methodes d'utilisation de ces anticorps et partenaires de liaison dans des processus inflammatoires
CA2366514A1 (fr) Utilisation a des fins diagnostiques et therapeutiques d'anticorps diriges contre le recepteur de l'urokinase
EP2583981A3 (fr) Anticorps et molécules correspondantes se liant aux protéines PSCA
WO2001091739A3 (fr) Compositions et procedes servant a traiter des maladies neoplasiques au moyen d'agents de sensibilisation a la chimiotherapie et aux rayonnements
WO2004069860A3 (fr) Proteines conjuguees a isg15

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase